Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases–U.S. Food and Drug Administration Joint Workshop

Publisher： John Wiley & Sons Inc

E-ISSN： 1527-3350|61|4|1392-1405

ISSN： 0270-9139

Source： HEPATOLOGY, Vol.61, Iss.4, 2015-04, pp. : 1392-1405

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Challenges and opportunities of pharmacogenetics in drug development

By March Ruth  

Personalized Medicine, Vol. 3, Iss. 2, 2006-05 ,pp. : 195-206

Future Medicine

Access to resources Recommend Favorite

Benefit‐risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation

By  

HEPATOLOGY, Vol. 67, Iss. 2, 2018-02 ,pp. : 482-491

John Wiley & Sons Inc

Access to resources Recommend Favorite

Proceedings of the Food and Drug Administration's public workshop on new red blood cell product regulatory science 2016

By  

TRANSFUSION, Vol. 58, Iss. 1, 2018-01 ,pp. : 255-266

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Precautionary Principle and the Regulation of U.S. Food and Drug Safety

By Soule Ed  

The Journal of Medicine and Philosophy, Vol. 29, Iss. 3, 2004-06 ,pp. : 333-350

Oxford University Press

Access to resources Recommend Favorite

Electron microscopic findings in non‐alcoholic fatty liver disease: Is there a difference between hepatosteatosis and steatohepatitis?

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 25, Iss. 3, 2010-03 ,pp. : 619-626

John Wiley & Sons Inc

Access to resources Recommend Favorite